Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • ALKS 8700: Phase I started

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Product: ALKS 8700 Business: Autoimmune Molecular target: NA Description: Small molecule prodrug of monomethyl fumarate (MMF) Indication: Treat multiple sclerosis (MS) …

    Published on 7/28/2014
  • APL-130277: Phase II started

    Cynapsus Therapeutics Inc. (TSX:CTH), Toronto, Ontario Product: APL-130277 Business: Neurology Molecular target: Dopamine receptor Description: Sublingual thin film strip formulation of apomorphine, a small molecule …

    Published on 7/28/2014
  • Atu027: Completed Phase Ib/IIa enrollment

    Silence Therapeutics plc (LSE:SLN), London, U.K. Product: Atu027 Business: Cancer Molecular target: Protein kinase N3 (PKN3) Description: Liposomal small interfering RNA (siRNA) formulation targeting protein kinase N3 (…

    Published on 7/28/2014
  • DCVax-Direct: Completed Phase I enrollment

    Northwest Biotherapeutics Inc. (NASDAQ:NWBO), Bethesda, Md. Product: DCVax-Direct Business: Cancer Molecular target: Not applicable Description: Autologous dendritic cells designed to uptake tumor antigens Indication: …

    Published on 7/28/2014
  • Eliquis apixaban: Phase IV started

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Eliquis apixaban (BMS-562247-01) Business: Cardiovascular Molecular target: Factor Xa Description: Direct Factor Xa …

    Published on 7/28/2014
  • Galactoarabino-rhamnogalacturonate: Phase Ib started

    Galectin Therapeutics Inc. (NASDAQ:GALT), Norcross, Ga. Product: Galactoarabino-rhamnogalacturonate (GR-MD-02) Business: Cancer Molecular target: Galectin-3 (LGALS3); Galectin-1 (LGALS1) Description: Galectin-3 (LGALS3)…

    Published on 7/28/2014
  • LMTX: Completed Phase III enrollment

    TauRx Pharmaceuticals Ltd., Singapore Product: LMTX (TRx0237) Business: Neurology Molecular target: Microtubule-associated protein tau (MAPT) (tau) (FTDP-17) Description: Second-generation tau aggregation inhibitor …

    Published on 7/28/2014
  • Locilex pexiganan acetate: Phase III started

    Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX), New York, N.Y. Product: Locilex pexiganan acetate (formerly Cytolex, MSI-78) Business: Infectious Molecular target: NA Description: 22-amino acid linear peptide with ability …

    Published on 7/28/2014
  • RUT58-60: Phase I started

    Ruthigen Inc. (NASDAQ:RTGN), Santa Rosa, Calif. Product: RUT58-60 Business: Infectious Molecular target: NA Description: Broad-spectrum anti-infective agent Indication: Adjunct therapy to systemic antibiotics to prevent…

    Published on 7/28/2014
  • SP-333: Completed Phase II enrollment

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), New York, N.Y. Product: SP-333 Business: Gastrointestinal Molecular target: Guanylate cyclase C (GCC) (GUCY2C) Description: Second-generation guanylate cyclase C (GCC; GUCY2C)…

    Published on 7/28/2014
  • TTP488: SPA received

    TransTech Pharma LLC, High Point, N.C. Product: TTP488 Business: Neurology Molecular target: Receptor for advanced glycation endproducts (RAGE) Description: Oral small molecule receptor for advanced glycation …

    Published on 7/28/2014
  • Viaskin Peanut: Completed Phase II enrollment

    DBV Technologies (Euronext:DBV), Bagneux, France Product: Viaskin Peanut (DBV-712) Business: Inflammation Molecular target: NA Description: Peanut proteins epicutaneously delivered by Viaskin patch technology Indication…

    Published on 7/28/2014
  • VivaGel astodrimer sodium: SPA received

    Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia Product: VivaGel astodrimer sodium (SPL7013) Business: Infectious Molecular target: Not available Description: Topical antimicrobial Indication: …

    Published on 7/28/2014
  • AYX1: Phase II started

    Adynxx Inc., San Francisco, Calif. Product: AYX1 Business: Neurology Molecular target: Early growth response 1 (EGR1) Description: Synthetic, dsDNA small molecule inhibitor of early growth response 1 (EGR1) Indication: …

    Published on 7/21/2014
  • CF102: Compassionate use program started

    Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-M:CANF), Petah Tikva, Israel Product: CF102 Business: Cancer Molecular target: Adenosine A3 receptor (ADORA3) Description: Nucleoside adenosine A3 receptor (ADORA3) agonist …

    Published on 7/21/2014
  • Clonidine: Completed Phase III enrollment

    Arcion Therapeutics Inc., Baltimore, Md. BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Product: Clonidine (clonidine topical gel) (formerly ARC-4558) Business: Neurology Molecular target: NA …

    Published on 7/21/2014
  • CTP-354: Phase I ongoing

    Concert Pharmaceuticals Inc. (NASDAQ:CNCE), Lexington, Mass. Product: CTP-354 (formerly C-21191) Business: Musculoskeletal Molecular target: GABA receptor Description: Deuterium-modified subtype-selective GABA A …

    Published on 7/21/2014
  • DEZ-001: Phase I start

    Dezima Pharma B.V., Naarden, the Netherlands Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: DEZ-001, TA-8995 Business: Endocrine/Metabolic Molecular target: Cholesteryl ester transfer protein (CETP) …

    Published on 7/21/2014
  • HaMPCs: Completed Phase IIb enrollment

    Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Product: HaMPCs, ReJoin Business: Autoimmune Molecular target: NA Description: Autologous human adipose tissue-derived mesenchymal precursor cells …

    Published on 7/21/2014
  • Inhaled nitric oxide: Completed Phase II enrollment

    Bellerophon Therapeutics LLC, Hampton, N.J. Product: Inhaled nitric oxide (NO) with the INOpulse DS drug-delivery system Business: Cardiovascular Molecular target: Not applicable Description: Combination product …

    Published on 7/21/2014
  • Nalbuphine ER: Phase II/III started

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Trevi Therapeutics Inc., New Haven, Conn. Product: Nalbuphine ER (T111) Business: Dermatology Molecular target: Mu opioid receptor (OPRM1) (MOR); Kappa …

    Published on 7/21/2014
  • Oxycodone/naltrexone: Pivotal trial started

    Elite Pharmaceuticals Inc. (OTCBB:ELTP), Northvale, N.J. Product: Oxycodone/naltrexone (ELI-201) Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: Abuse-deterrent formulation of …

    Published on 7/21/2014
  • Palovarotene: Phase II started

    Clementia Pharmaceuticals Inc., Dorval, Quebec Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Palovarotene (R667) (formerly RG667, CLM-001) Business: Musculoskeletal Molecular target: Retinoic acid receptor …

    Published on 7/21/2014
  • ProCervix: Phase II ongoing

    Genticel S.A. (Euronext:GTCL), Labege, France Product: ProCervix Business: Cancer Molecular target: Human papillomavirus (HPV) antigens Description: Bivalent therapeutic cancer vaccine against HPV types 16 and 18 …

    Published on 7/21/2014
  • QPI-1007: Phase IIa started

    Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India BioSpring GmbH, Frankfurt, Germany Kunshan RiboQuark Pharmaceutical Technology Co. Ltd., Kunshan, China SBI Biotech Co. Ltd., Tokyo, Japan Product: QPI-1007 …

    Published on 7/21/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993